A few weeks ago, the Enlarged Board of Appeal of the European Patent Office (EPO) issued a decision on the extent to which computer-implemented simulations are patentable in Europe (previously reported here). The confirmation that computer-implemented simulations should be considered in the same way as any other computer-implemented process could be significant for the industry that filed more European patents than any other in 2020: Medical Technology.
The Internet of Medical Things (IoMT) is a subsection of the more well-known Internet of Things. Broadly, the IoMT is a connected infrastructure of medical devices, software applications, and health systems and services. This infrastructure aims to improve accessibility of healthcare, while improving patient health and satisfaction with healthcare services. In 2016, it was predicted that by the year 2020, 40% of IoT technology will be health related1 (more than any other subsection). It has also been predicted that by 2022, the IoMT market will be worth roughly US$158 billion2, compared to a comparatively measly US$24 billion in 20163. We at Reddie & Grose have been closely following the progress of the IoMT which encompasses many rapidly advancing technologies and a number of potentially patentable areas.
Electroceuticals are therapeutic agents that help to heal the body with minute pulses of electricity. Treating the human body with electricity has a chequered history, but the understanding that the nervous system can be stimulated by electricity impulses is attributed to the experiments of Galvani in the late 18th century.